Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Dipeptidyl-Peptidase IV Inhibitors 3Vildagliptin 2Sulfonylurea Compounds 2Sitagliptin Phosphate 2Rosiglitazone 2Pioglitazone 2Metformin 2voglibose 1somapacitan 1semaglutide 1saxagliptin 1repaglinide 1miglitol 1metahexamide 1meglitinide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1alogliptin 1Urine Specimen Collection 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1Surveys and Questionnaires 1Sodium-Glucose Transporter 2 Inhibitors 1Phenformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Diabetes Mellitus, Type 2 × empagliflozin × Clear all
NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

Completed
344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡